Perspective Therapeutics, Inc. · AMEX:CATX
Perspective Therapeutics — Investor Presentation (February 2024)
88 slides from Perspective Therapeutics's investor presentation, Feb 5, 2024
Slide 1: Corporate Presentation
PERSPECTIVE THERAPEUTICS Corporate Presentation NYSE: CATX
Slide 2: Legal Disclaimers
Legal Disclaimers ‘This presentation contains forwardJookng statements within the meaning ofthe United States Private Securties Ligation Reform Act of 1995. Statements in this presentation that are not Statements of nistorcal fact are forwarcooking statements. Words such as “may,” “wil” “shoul,” “ex
Slide 3: Investment Highlights
Investment Highlights Platform radiopharmaceutical company targeting pan-cancer Proprietary chelator-based peptide target opportunities utilizing 2" generation -emitter provides engine for pipeline expansion PERSPECTIVE ot AY penseec
Slide 4: Platform Expansion Engine
Platform Expansion Engine Two Lead Programs in Clinicand Broad Proprietary Pipeline VMT@NeT veto vMTO2(PETagent) PSV350 (Novel peptide) | PSv401,Radio-rybria) Program5 (Novel peptide) Pre-targeting Platiorm (mAbs) Other Programs Novel peptides) %| Indication Neuroendocrine cancers Pheochromocytomas,
Slide 5: Pipeline With Multiple Expected Near-Term Data Readouts
Pipeline With Multiple Expected Near-Term Data Readouts ee a os meta 2a nce nent ‘Seer eywn ewer pny, i woo peng ieee a : =, ein 9 — See sl PY perspective THERAPEUTICS
Slide 6: Management Team
Management Team Deep Experience in Radiopharmaceuticalsand Oncology Drug Development Thijs Spoor Chief Executive Officer 20+ years of expertise in biotechnology ‘companies; public and private companies; ‘oncology and nuclear pharmacy Jonathan Hunt Chief Financial Officer 20+ years of expertise in fi
Slide 7: Radiopharmaceuticals are a Pillar of Oncology Treatment
Radiopharmaceuticals are a Pillar of Oncology Treatment Unique Mechanism of Action Offers Pan-Cancer Opportunities Radioligands can precisely deliver radiation directly to cancer cells reducing offtarget effects Proven pillar of cancer treatment Perspective's platform technology's optimized for grea
Slide 8: Perspective's Radiopharmaceutical Optimization Process
Perspective’s Radiopharmaceutical Optimization Process Unique Mechanism of Action Offers Pan-Cancer Opportunities Targeting Peptide Engineered for cance specific receptors to sure highly ted uptake Linker Chelator 1d to assist peptide binding Perspective's imize clearance from blood technology enal
Slide 9: Lead-212: The Optimal Therapeutic Isotope
Lead-212 (2!2Pb): The Optimal Therapeutic Isotope Alpha Particles Provide Numerous Benefits Over Currently Used Beta Particle Radiotherapies + With a much higher atomic mass, alpha (a)particles generate more energy and travel a shorter distance compared to beta (B) particles, making them more cytoto
Slide 10: Chelator Optimized for 212/203Pb
Chelator Optimized for “2/23Pp Perspective's Enabling Technology for Pb-based Radiopharmaceuticals = sun = + Designed specifically for Pb isotopes HN. + Optimized for rapid renal % NET2- “whe ae 2+ ° NETO clearance through neutralized formal charge nee IL + Improves redlabeting Zapp ence abs recepto
Slide 11: Pb-based Theranostics Enable Both Diagnosis and Targeted Treatment of Cancer
Pb-based Theranostics Enable Both Diagnosis and Targeted Treatment of Cancer Identical Distribution of °°Pb and!?Pp for Imaging and Treatment, Respectively Imaging — = 24 hours Cancer Cell mph r} Patient selection tT Dosimetry: T,,, = 52h ; pb can be used Linker to establish "Pb pharmacokinetics Mat
Slide 12: Neuroendocrine Tumors: VMT-a-NET
Neuroendocrine Tumors: VMT-a-NET Targeting the somatostatin receptor to treat rare neuroendocrine- type cancers PERSPECTIVE A rae
Slide 13: VMT-α-NET Currently in Phase 1/2a Studies: Key Facts
VMT-o-NET Currently in Phase1/2a Studies: Key Facts Targeting somatostatin receptor type 2 (SSTR2) or the imaging and treatment of neuroendocrine tumors Initiated first-in-human imaging (2021) & therapy (2022) under compassionate use Fast Track Designation for first line therapy received October 202
Slide 14: SSTR2 is an Attractive Target for Identifying and Treating Tumors
SSTR2 is an Attractive Target for Identifying and Treating Tumors Expressed Across Several Tumor Types Neuroendocrine tumors (NETS) + Neuroendocrine cells are specialized cells that secrete hormones and other bioactive substances + Neuroendocrine cells are found throughout the body + Often grow in t
Slide 15: Decreased Off-Target Toxicity, Increased Tumor Uptake and Retention in Preclinical Studies
Decreased Off-Target Toxicity, Increased Tumor Uptake and Retention in Preclinical Studies SSTR2 tumor model demonstrates superiority of VMT- @-NET to generic compounds 8-fold improved tumor uptake with decreased kidney retention PERSPECTIVE
Slide 16: VMT-α-NET Shows Significant Improvement vs Standard of Care in Preclinical Models
VMT-o-NET Shows Significant Improvement vs Standard of Care in Preclinical Models Superior Efficacy with Single Dose or Multiple Administrations in AR42J SSTR2-Expressing Tumor 20. Fo. Joe. 3 10. [°?"LupOTATATE Fo. (3x500uc) % Cn a ee if Days posttreatment sn (??PbVMT-ONET [??PbVM-o-NET j 1000 (1x 1
Slide 17: 203Pb SPECT Imaging Reveals Favorable VMT-α-NET Properties
203Pb SPECT Imaging Reveals Favorable VMT-o-NET Properties” Rapid Tumor Targeting High Tumor and Renal Clearance Retention + Tumors visible within 1 hour indicates rapid binding to SSTR2 target + High intensity above background Pa + ? a? rz implies excellent therapeutic window —e - 7 si + Unbound dr
Slide 18: SPECT/CT Imaging Time Points
1.5 hrs SPECT/CT 22 hrs ‘SPECT/CT 19.5 hrs > spect/ct PERSPECTIVE
Slide 19: Significant Response After Single Dose of [212Pb]VMT-α-NET
Significant Response After Single Dose of [2!2Pb]VMT-c-NET Metastatic NET Pancreas with Adrenal Crisis - Maximum Intensity Projection (MIP) Tumor Before Treatment Tumor After 1 Dose + ©§Ga-DOTA-NOC PET images at base line and post 1st dose of (22Pb]VMT-o-NET + MIP suggesting strong reduction of inte
Slide 20: Almost Complete Response After Doses of [212Pb]VMT-α-NET
Almost Complete Response After 3 Doses of [72Pb]VMT-o-NET Metastatic NET Pancreas with Adrenal Crisis - [°°Ga]DOTATOC PET/CT Images Tumor Before Treatment °) e Tumor After 3 Doses (SACTH)!~ 790 pg/ml SACTH - 96 pg/ml 36 FD) PERSPECTIVE
Slide 21: Clinical Investigation of [212Pb]VMT-α-NET in Metastatic SSTR2 Positive Patients
‘Treating Physician: Dr. Ishita B Sen Director & Head Dept of Nuclear Med. & Molecular Imaging, Fortis Memorial Research Institute, Gurgaon, India Clinical Investigation of [2!2Pb]VMT-c-NET in Metastatic SSTR2 Positive Patients Interim Results as of September 28, 2023. for Ongoing Investigation in I
Slide 22: High Partial Response Rate at Starting Dose in Patients with SSTR+, Late-Stage NETs
High Partial Response Rate at Starting Dose in Patients with SSTR+, Late-Stage NETs Interim Results as of September 28, 2023, for Ongoing Clinical Investigation Program in India va spa bos ak Per @x Patents a * © rremecsr Pe Bk Patents exp nest) ke cine ex Patient > pr inecsn vee ener Ce arenes) ee
Slide 23: Trial Design: [212Pb]VMT-α-NET Phase 1/2a For Neuroendocrine Tumors
Trial Design: [72Pb]VMT-o-NET mTPI-2! Phase 1/2a For Neuroendocrine Tumors Primary Objective: ‘To determine the MTD/MFO of [22Pb]VMT-c-NET (RP2D) Imaging FDA approved SSTR2 PET/CT _ : is lie salon al a ing kaon ne 1032 Torpedo diane roan Popustion: Unresectable or metastatic SSTR2-positive NETS Esti
Slide 24: Melanoma Program: VMT01/02
Melanoma Program: VMT01/02 Using the melanocortin receptor MC1R to target melanoma for imaging and therapy
Slide 25: Slide 25
Slide 26: Metastatic Melanoma
Metastatic Melanoma [?22Pb]VMTO1 target indication: MCAR-positive melanoma + Projected market opportunity for melanoma of $8 billion+ in 2028 + Significantunmet needin the US: Liver + ~100K new diagnoses annually? + ~8,000 people die from melanoma every year? Treatment depends on the stage of tumor
Slide 27: [68Ga]VMT02 PET Imaging in Patient with MC1R Positive Metastatic Melanoma
[®Ga]VMTO2 PET Imaging in Patient with MC1R Positive Metastatic Melanoma Diagnostic Peptide Demonstrates Similar Uptake to FDG in Tumors 18F-FDG (Standard of Care) [s8Ga]vMT02 Patient information: (Ea + Male, Asian, 33 years old * [68Ga]VMTO2: 7 mCi injection, 45 min post- injection imaging Clinical
Slide 28: Slide 28
Slide 29: [212Pb]VMT01 in Combination Demonstrates Synergistic Responses
[2Pb]VMTO1 in Combination Demonstrates Synergistic Responses Multiple Melanoma Tumor Models Show Promise of Combining with Standard of Care Key Takeaways + High response rates in multiple tested models + 43% complete and durable response if combined with immunotherapy in a model highly resistant to
Slide 30: Trial Design: [212Pb]VMT01-T101 mTPI2 Phase 1/2a For Metastatic Melanoma
Trial Design: [72Pb]VMT01-T101 mTPI1 Phase 1/2a For Metastatic Melanoma PrimaryObjective: To determine the MTO/MFO of [2Pb]VMTO1 (RP20) Imaging, ["Pb]VMTOL SPEC/CT or [*Ga]VMTO2 PET/CT 3 ~ 15 mCi dose escalation with fixed dosing every & ‘Screen ~120 subjects imhemeoisio ese: weeks for upto 3 cycles
Slide 31: Prostate Cancer Program: PSV401
Prostate Cancer Program: PSV401 A differentiated PSMA-targeted radiohybrid molecule for dual PET imaging and targeted alpha therapy
Slide 32: Prostate Cancer Program: PSV401
Prostate Cancer Program: PSV401 A differentiated PSMA+targeted radiohybrid molecule for dual PET imagingand targeted alpha therapy PSMA is a clinically and commercially validated target for radioligand therapy Combines t single targeting ligand to provide Different identi s and therape Chelators in
Slide 33: Pre-Targeting Platform
Pre-Targeting Platform The Next Generation of Targeted Alpha Particle Radiopharmaceuticals
Slide 34: Pre-Targeting Platform Background
Pre-Targeting Platform Background Relies on the different kinetics of large proteins and small moleculesand a multi-step process © ramninister cot moaitied monoctonat antivody or targeting protein © weer severat cays. mab will have accumulated on tumor and cleared from blood (3] Administer radiolabe
Slide 35: Manufacturing, Production and Logistics of 212Pb-labeled Therapeutics
Manufacturing, Production and Logistics of 2!2Pb- labeled Therapeutics The Path to Commercial Supply
Slide 36: 212Pb is Plentiful, Storable, Scalable & Suitable for Distributed Logistics
212Pb is Plentiful, Storable, Scalable & Suitable for Distributed Logistics The supply chainis lowerriskand more robustthan other therapeuticisotopes Isotope Source Isotope Purification Product Manufacturing ‘Also produced it & Naturally occurring in mining waste industrial nuclear processes Can be
Slide 37: Isotope Decay Chain Dictates Supply, Purification, Manufacturing & Logistics
Isotope Decay Chain Dictates Supply, Purification, Manufacturing & Logistics Naturally Occurring lsotope Decay - No Irradiation Processes Required Plentiful Supply: Naturally occurring, or produced as a waste product + Multiple global suppliers including natural decay + 2year halflife allows stockpi
Slide 38: 212Pb Isotope Purification Without Just-in-time Irradiation
212Pb Isotope Purification Without Just-in-time Irradiation ‘Simple chemical separation technology of natural decay products de-risks supply chain Inlet B c Solvent — T=) © Chromatography) Immobilized Accumulation | Retention on ® 2IRa - of 222Pb - of 24Ra - retains|perent a ee produces 22Pb natural
Slide 39: 212Pb Supply via Reusable Desktop Isotope Generator
222Pb Supply via Reusable Desktop Isotope Generator VMT-a-GEN + Extensive feedstock from nuclear and mining waste material + Long-term supply contract secured with US DOE + On demand daily doses — Auto-regenerates overnight — ~L week sheff life die ‘Small, Elegant 212Pb Isotope Generator VL Bi + Int
Slide 40: Scalable Manufacturing and Distribution Logistics
Scalable Manufacturing and Distribution Logistics Perspective'splanto flexiblyscale manufacturingto commercial levels (100,000+doses per year) cererator pantacured centr _ z ‘and shipped eluted for 242PD ‘0007 ‘eco fol = - - B&- , row Fs aoe Ss eouok Large Moule Ey fim rector erent & Srectrtouse ete
Slide 41: Isotope Decay Chain Dictates Supply, Purification, Manufacturing & Logistics
Isotope Decay Chain Dictates Supply, Purification, Manufacturing & Logistics Naturally Occurring Isotope Decay - No Irradiation Processes Required Central continental supply Eluted weekly for 2Ra ‘+ Distributed continentally Eluted daily for?#Pb Daily manufacture of finished doses Leverages existing
Slide 42: Infrastructure and Distribution Networks for Radiopharmaceuticals are Mature
Infrastructure and Distribution Networks for Radiopharmaceuticals are Mature Existingradiopharmacies have established logistics for distributed supply Map of US Radiopharmacies* + There were 40+ million diagnostic nuclear medicine procedures performed in the US in in 2022 + Multiple networks exist i
Slide 43: Regional Manufacturing Allows Commercialization of 212Pb-labeled Finished Products
Regional Manufacturing Allows Commercialization of 2“*Pb4abeled Finished Products Limited number of sites allows for “network effect” to ensure robustsupply chain Locat Coralville, 1A Sim New York, NY 75m Los Angeles, CA 46m Austin, TX 32m Atlanta, GA 57m Central Florida, FL 25m ‘Top 6 sites cover n
Slide 44: Strong Intellectual Property Portfolio
Strong Intellectual Property Portfolio Fully Licensed University/Perspective-owned IP 4 provisional patents + Composition of Matter and Use radiometal separations technology, novel pan-cancer product . generator technologies (US. E.U., Australia) 3 non-provisional patent applications. + Composition
Slide 45: Appendix
Appendix
Slide 46: Targeting cancer from the inside out
Targeting cancer from the inside out We are developing game-changing Precision Medicine Therapeutics which harness the power of targeted Alpha-Particle Radiotherapies that make an impactful difference for cancer patients and the clinicians who treat them.
Slide 47: Who We Are
Who We Are Perspective Therapeutics (NYSE CADY)is a clinical stage precision medicine company, debuting as a public companyin 2023 With a broad pipeline and two prioritized lead programs in clinic, we are disrupting traditional radiation therapy treatment for cancer though developinga new class of i
Slide 48: α-Particles Have Superior Tumor Killing Properties vs. β-Particles
a-Particles Have Superior Tumor Killing Properties vs. B-Particles More Powerful Effects Than Approved B Therapy Precision Delivery Provides Targeted Cell Destruction 48 | suet coconut anata 208 Higher atomic mass Lethal double-stranded DNA breaks DNA repair mechanisms overwhelmed Deposit energy ove
Slide 49: Lead-212: The Optimal Therapeutic Isotope
Lead-212 (2!2Pb): The Optimal Therapeutic Isotope Greater Therapeutic Energy Expected to Improve Outcome with Better Safety Alpha particle range (up to 3 cell diameters) Beta range (up to 200 cell diameters) Tumor Cells Normal Tissue + oamm amm on Tumor Healthy tissue The destructive energy of an al
Slide 50: Lead (Pb): The Ideal Theranostic Isotope
Lead (Pb): The Ideal Theranostic Isotope Ideal Theranostic Requirements Ideal agreement between imaging and therapeutic compounds: Readily available isotope Ideal chelator Rapid clearance from blood High tumor retention @24 hours ‘Short-¥6 gives rapid effect while minimizing environmental impact No
Slide 51: Peptides are Ideal Ligands for Radiopharmaceutical Therapy
Peptides are Ideal Ligands for Radiopharmaceutical Therapy Monoclonal antibodies Peptides Tumer penetration: | Low Manufacturing: | Complex bilogeal Tumer penetration: | High Manufacturing: | Syhete earance Hepatoolany wer) | | Cote: ign Cearance: Renal (oneys) ces: Very ow Boogeal ure | Long Boogea
Slide 52: VMT-α-NET is Developed to Address the Unmet Need in NETs
VMT-a-NET is Developed to Address the Unmet Need in NETs CurrentStandard of Care limited to subset of NETs patients z NETTER-1 Study Finaloverall survival? Significant unmet need: + ~12K new diagnoses annually in the US* Sassen conten + ~175,000+ people are living with this diagnosis in the US* Mark
Slide 53: 225Ac Isotope Decay Chain and Potential for Off-Target Toxicity
225Ac Isotope Decay Chain and Potential for Off-Target Toxicity Alpha-particle emission imparts sufficient “recoil” energy to break chemical bonds ‘Aro04 19812140 20) enuonog PERSPECTIVE
Slide 54: Isotope: Decay chain - Product implications
Isotope: Decay chain - Product implications Post final radiolabelingand purification, alpha and beta emitting daughters of 225Ac build up fast Radioactivity (Bq) A Decay and Daughter ingrowth WAC225 mFr221 mAL2I7 mBi213 = T1209 mPo-213 2 3 4 Hours Post Purification 1 kBq 225Ac starting dose size. Do
Slide 55: 212Pb Isotope Decay Chain and Importance of the Pb-Specific Chelator
22Pb Isotope Decay Chain and Importance of the Pb-Specific Chelator Isotope Supply Production 55 | swizaden eta, Raciochimca Acta, 1993 Where the drug goes = where the alpha particle is deposited OH + Perspective’s proprietary chelator retains 98% of 2328] after transition in drug formulation + Gene
Slide 56: Clinical Collaborators and Investigators
GeoffreyB. Johnson MD, PhD RE Chair, Division of Nuclear Medicine Chair, PET/MR RED Associate Professor Departments of Radiology and Immunology Mayo Clinic - Rochester, MN Vikas Prasad MD Professor of Radiology ES Associate Professor Radiology, Division of Nuclear Medicine Washington University in S
Slide 57: Appendix: VMT-α-NET
Appendix: VMT-o-NET
Slide 58: Significant Tumor Response After Two Doses
Significant Tumor Response After Two Doses Patient: Metastatic NET Pancreas with Liver Metastases MIP image Before Treatment MIP image After 2nd Treatment Liver Metastases after treatment with two doses FD) PERSPECTIVE
Slide 59: Reduction in Size of Necrotic Masses After Doses
Reduction in Size of Necrotic Masses After 2 Doses Patient: Pancreatic NET Tumor Before Treatment Tumor After Treatment
Slide 60: Favorable Safety and Tolerability Profile
Favorable Safety and Tolerability Profile FourMonths Post-Treatment (5 Patients) moglobin Levels Total Leukocyte Coun Hemewou nem, “ 2000 20 ‘2000 : 2000 ° ° z Fy 2 Fy ‘mE qHoNTs) "we wonTis) PUTELETCOUNT —e=Paet —m—Patrt2 —e- Patent —oePoter Patents —e Patent a Poter2 a Patert3 oe Patines Pateres ‘
Slide 61: Serious Adverse Event in Patient
Serious Adverse Eventin Patient 2 Myelodysplastic syndrome (MDS) Unrelatedto Study Drug Pre-Therapy a , Post-Therapy Patient Profile 79 year-male Metastatic Medullary Carcinoma thyroid Disease progression of TKI's Received total 3 doses of [71?Pb]VMT-o-NET therapy at an interval of 8 weeks (Cumulati
Slide 62: Serious Adverse Event in Patient
Serious Adverse Eventin Patient 6 Acute Cardiac Event Unrelated to Study Drug Significanttumor burden Patient Profile 25 year-male Metastatic NET-pancreas Long-standing disease (>6 years duration) Heavily pretreated with Inj. Sandostatin and 4 cycles of 177Lu- DOTATATE along with CAPTEM regimen Rece
Slide 63: Appendix: Prostate Cancer Program - PSV401
Appendix: Prostate Cancer Program - PSV401
Slide 64: Typical Theranostic Approach: One Molecule, One Chelator, One Isotope
Typical Theranostic Approach: One Molecule, One Chelator, One Isotope Separate But Chemically Identical Molecules Labeled with Either2°°Pb or 2!2Pp for Imagingand Treatment, Respectively Note: One chelator ‘24 hours: Cancer Cell mph One isotope r} Imaging Patient selection tT Dosimetry: T,,, = 52h ;
Slide 65: PSV401 DoubLET: One Molecule, Two Chelators, Four Possible Isotopes
PSV401 DoubLET*?: One Molecule, Two Chelators, Four Possible Isotopes One Molecule Labelled with Two Elementsat Once, with Isotope Selection Determining Diagnosticor Therapeutic Two chelators on one targeting ligand a The C Each can be labeled with stable or radioactive atoms euTnatcy entity to trea
Slide 66: PSV401 Has Potential to be Best-In-Class Prostate Cancer Targeted Alpha Therapy
PSV401 Has Potential to be “Best-In-Class” Prostate Cancer Targeted Alpha Therapy CurrentStandard of Care with Beta-Based Radiopharmaceuti Significant Unmet Need: + ~288K newdiagnoses annually in the US* + ~3.3M# men iving with this diagnosis in the US* + ~35Kdeaths annually in the US* Market Opport
Slide 67: PSV401: Preclinical 64Cu PET Imaging Data Showing Tumor Uptake
PSV401: Preclinical ©Cu PET Imaging Data Showing Tumor Uptake Rapid Tumor Uptake and Effective Renal Clearance with Radioactive Imaging Isotope Key Takeaways PSMA+ LNCaP tumor 15 min p.i. 30 min p.i. 60 min p.i. model suggests A, [etcuypsv4o1 targets Coronal Sagittal Coronal Sagittal Coronal Sagitta
Slide 68: PSV401: Preclinical Comparison to Industry Standard
PSV401: Preclinical Comparison to Industry Standard* (Cu]PSV401 Compares Favorably to FDA-Approved Imaging Agent [Ga]PSMA-11 (ILLUCCIX®, Telix)? 15 min p.i. 30 min p.i. 60 min p.i. 120 min pi. Sagittal Sagittal Sagittal Coronal [®Ga]PSMA-11 eS Coronal Sagittal Coronal Sagittal, Coronal Sagittal Coro
Slide 69: PSV401: Preclinical Comparison to Industry Standard
PSV401: Preclinical Comparison to Industry Standard [Cu]PSV401 Significantly" Improved Uptake/Clearance Compared to [°°Ga]PSMA112 Tumor Retention Kidney Retention Salivary Gland Retention —~ (caypsMatt fee : . (icapsmaat =) pore ee 22? ] 3° a 31 r + 5 3 $ ; 5 2 ~ (capsmatt gy m+, Bw 6 2 08 2 g fecup
Slide 70: Preclinical [212Pb]PSV401 Therapy
Preclinical [2'2Pb]PSV401 Therapy Preliminary[22Pb]PSV401 Data Shows Potentialto Effectively Kill Tumors* + Allimaging performed with [*Cu]PSV401 microPET + Treatment of PSMA+ prostate cancer xenograft with [212Pb]PSV401 reduced tumor size 38% in 3 days and complete response after 9 days * Additiona
Slide 71: Mayo Clinic Inventors
Mayo Clinic Inventors Licensing Continues a Long & Productive Alliance Exclusive world-wide license to Mayo’s NSN24901/AlphaPET-PSMAO1 Molecule 3S Mukesh Pandey, PhD, FRSC (PSV401) Director, Mayo Clinie Molecular Imaging Research Program Professor of Radiology Mayo Clinic ~ Rochester, MN Includes Bo
Slide 72: Appendix: Manufacturing, Production and Logistics of 212Pb-labeled Therapeutics
Appendix: Manufacturing, Production and Logistics of 212Pb-abeled Therapeutics
Slide 73: Isotope Decay Chain Dictates Supply, Purification, Manufacturing & Logistics
Isotope Decay Chain Dictates Supply, Purification, Manufacturing & Logistics Naturally Occurring Isotope Decay - No Irradiation Processes Required Plentiful Supply: Naturally occurring, or produced as a waste product ‘Chemical Separation: Allows for Ra-based generators of 242Pb ‘Chemical Separation
Slide 74: Parent Isotope Source
Parent Isotope Source Key Isotopes for Supply: 22°Th and 24Ra 228Th half-life of 1.9 years allows long term storage and extraction of daughter 2*Ra Th ys 224Ra grows in naturally (without irradiation) from 228Th decay Perspective currently has a 10 year supply agreement with US Department of Energy
Slide 75: Flexible and Scalable Isotope Supply
Flexible and Scalable Isotope Supply 224Ra enables Regional Manufacturing Hubs. Th 224Ra half-life of 3.6 days allows weekly shipments to regional manufacturing sites — pasa 22d — teb222 Time (days) 212Ph grows in naturally (without irradiation) from ?4Ra decay Perspective's proprietary VMT-«-GEN en
Slide 76: Isotope Decay Chain Dictates Supply, Purification, Manufacturing & Logistics
Isotope Decay Chain Dictates Supply, Purification, Manufacturing & Logistics Naturally Occurring Isotope Decay - No Irradiation Processes Required + Central continental supply + Eluted weekly for2Ra + Distributed continentally + Eluted daily for2Pb + Daily manufacture of finished doses + Leverages e
Slide 77: 212Pb is Plentiful, Storable, Scalable & Suitable for Distributed Logistics
212Pb is Plentiful, Storable, Scalable & Suitable for Distributed Logistics The supply chain is lowerriskand more robust than other therapeuticisotopes Isotope Source Isotope Purification Product Manufacturing ‘Also produced it & Naturally occurring in mining waste industrial nuclear processes Can b
Slide 78: Parent Isotope Source
Parent Isotope Source + Storage of thorium-228 (half-life of 1.9 years) allows for “on-demand” purification of Ra-224 and Pb-212 ‘+ Multiple purification/production methods for Th-228 with different starting materials and processes, including Ra-228 generators (half- life 5.7 years) + Ra-224 (halfli
Slide 79: Parent Isotope Supply
Parent Isotope Supply Producedas a waste = product, 10s of Ci available + Thorium-228 is available as a natural isotope but is also produced as a waste product from the nuclear fuel cycle, and as a result of production of therapeutic isotope Ra-223 (marketed as Xofigo. Bayer) + Both Ac-227 (the pare
Slide 80: Pb-212 Isotope Purification
Pb-212 Isotope Purification N tion paths to Pb-212 availa tiple px ‘+ Similar in size to Ga-68 generators + Useful or preclinical R&D and clinical trials, + Nimble, portable supply available for either local or regional production + Typically chromatography column based. + Using Ra-224 as parent + S
Slide 81: Slide 81
Slide 82: Slide 82
Slide 83: Slide 83
Slide 84: Slide 84
Slide 85: Slide 85
Slide 86: Slide 86
Slide 87: Slide 87
Slide 88: Slide 88
Perspective Therapeutics — Investor Presentation (February 2024) on 6ix